---
figid: PMC11603874__13046_2024_3218_Fig4_HTML
figtitle: TNFR2/Mb-TNFA signalosome pathway
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11603874
filename: 13046_2024_3218_Fig4_HTML.jpg
figlink: /pmc/articles/PMC11603874/figure/F4/
number: F4
caption: TNFR2/Mb-TNF-α signalosome pathway. Upon Mb-TNF-α binding to TNFR2, the T2bs-N
  region recruits TRAF2, which then recruits E3 ligases (cIAP1, cIAP2, RIP, and LUBAC).
  LUBAC attaches M1-linked ubiquitin chains, stabilizing the signaling complex and
  enhancing downstream signaling. This leads to the accumulation of TRAFs 1, 3, 5,
  and 6, which phosphorylate TRAF 3, releasing NIK. NIK stimulates MEKK1, 2, 3, and
  TAK1, which then phosphorylate, IKKα, IKKβ, IKKε, and KKγ, inducing NF-κB pathways.
  Inhibitors like Celecoxib, CYLD, and MG-132 can prevent NF-κB activation. In addition,
  cIAP1 and cIAP2 stimulate BMX and JNK/cJUN, which induce PI3K/Akt, resulting in
  the activation and phosphorylation of several pathways (ETK/VEGFR2, ERK1/2, IGF1,
  HER2, mTOR, NF-κB, FOXO3a, and PD-L1). HER2 and ERK1/2 induce positive feedback
  loop signals, which enhance BC cell metabolism and proliferation via NF-κB, c-MYC,
  STATs, SAP-1a, AP-1, Elk-1, Cyclin D1, and ER. TNFR2 also stimulates HIF-1α, which
  in turn activates VEGF and its associated signaling pathways, leading to NF-κB-p65
  activation. TNFR2 in its promoter contains binding sites for both STAT3 and c-AMP,
  the binding of which induces TNFR2 overexpression. Epigenetically, TNFR2 enhances
  IL-6 overexpression and down-regulates TET1 expression. As a result of TNFR2 activation,
  multiple proteins will be stimulated (CCL-2, PDL-1, IL-1β, IL-6, IL-8, IL-10, IL-23,
  M-CSF, MMP-9, COX-2/PGE2, TGF-β, CXCR4/CXCL-12, TNF-α, TNC, IFN-γ, and HIF-1α),
  leading to drug resistance, altered metabolism, migration, invasion, and the development
  of EMT. TNFR2, tumor necrosis receptor type 2; Mb-TNF-α, membrane-bound tumor necrosis
  factor; TRAF, TNF receptor associated factor; T2bs-C, TRAF2-binding site C; T2bs-N,
  TRAF2-binding site N; cIAP, cellular inhibitor of apoptosis; SHARPIN, shank-associated
  RH domain-interacting protein; HOIL-1-K63-Ub, heme-oxidized IRP2 ubiquitin ligase
  1; HOIP-M1-Ub, HOIL-1-interacting protein; LUBAC, linear ubiquitin chain assembly
  complex; NIK, activate NF-κB inducing kinase; MEKK, MAP kinase/ERK kinase; TAK1,
  transforming growth factor-activated kinase 1; TAP, TAK1-binding protein complex;
  PI3K, phosphoinositide 3-kinases; Akt, protein kinase B/serine-threonine kinase;
  CYLD, cylindromatosis; PFK-2, phosphofructokinase-2; PFKFB2, 3, 6-phosophofrcto-2-kinase/fructose-2,
  6-biphosphatase 3; mTOR, mammalian (or mechanistic) target of rapamycin; EGFR, epidermal
  growth factor receptor; PTEN, phosphatase and tensin homolog; VEGF, vascular endothelial
  growth factor; ETK, endothelial/epithelial tyrosine kinase; BMX, marrow x-linked
  kinase; VEGFR2, vascular endothelial growth factor receptor 2; EMT, epithelial-mesenchymal
  transition; MMP-9, matrix metalloproteinase-9; FOXO3a, forkhead box O3a; JNK, c-jun
  N-terminal kinase; ERK, extracellular signal-regulated kinase; MUC-1 and MUC1-C,
  Mucin; c-MYC, cellular myelocytomatosis; STAT, signal transducer and activator of
  transcriptions; AP-1, activator protein-1; IL-6, interleukin 6; IL-8, interleukin
  8; IL-10, interleukin 10; IL-23, interleukin 23, M-CSF, macrophage colony stimulating
  factor; TET, ten-eleven translocation; COX-2, cyclooxygenase-2; PGE2, prostaglandin
  E2; TGF-β, transforming-growth factor β; IFN-γ, interferon gamma; HIF-1α, hypoxia
  inducible factor 1 alpha; NRP-1, Neuropilin-1; TNC, Tenascin C; ITBG3, integrin
  3; FAK, focal adhesion kinase pathway; IKKs, IκB kinases; IGF1, insulin-like growth
  factor 1; HER2, human epidermal growth factor receptor 2
papertitle: Understanding the role of TNFR2 signaling in the tumor microenvironment
  of breast cancer
reftext: Ali Mussa, et al. J Exp Clin Cancer Res. 2024;43(NA).
year: '2024'
doi: 10.1186/s13046-024-03218-1
journal_title: 'Journal of Experimental & Clinical Cancer Research : CR'
journal_nlm_ta: J Exp Clin Cancer Res
publisher_name: BMC
keywords: Immune checkpoint | Immunosuppressive TME | TNF | TNFRSF1B | CD120b
automl_pathway: 0.9126412
figid_alias: PMC11603874__F4
figtype: Figure
redirect_from: /figures/PMC11603874__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11603874__13046_2024_3218_Fig4_HTML.html
  '@type': Dataset
  description: TNFR2/Mb-TNF-α signalosome pathway. Upon Mb-TNF-α binding to TNFR2,
    the T2bs-N region recruits TRAF2, which then recruits E3 ligases (cIAP1, cIAP2,
    RIP, and LUBAC). LUBAC attaches M1-linked ubiquitin chains, stabilizing the signaling
    complex and enhancing downstream signaling. This leads to the accumulation of
    TRAFs 1, 3, 5, and 6, which phosphorylate TRAF 3, releasing NIK. NIK stimulates
    MEKK1, 2, 3, and TAK1, which then phosphorylate, IKKα, IKKβ, IKKε, and KKγ, inducing
    NF-κB pathways. Inhibitors like Celecoxib, CYLD, and MG-132 can prevent NF-κB
    activation. In addition, cIAP1 and cIAP2 stimulate BMX and JNK/cJUN, which induce
    PI3K/Akt, resulting in the activation and phosphorylation of several pathways
    (ETK/VEGFR2, ERK1/2, IGF1, HER2, mTOR, NF-κB, FOXO3a, and PD-L1). HER2 and ERK1/2
    induce positive feedback loop signals, which enhance BC cell metabolism and proliferation
    via NF-κB, c-MYC, STATs, SAP-1a, AP-1, Elk-1, Cyclin D1, and ER. TNFR2 also stimulates
    HIF-1α, which in turn activates VEGF and its associated signaling pathways, leading
    to NF-κB-p65 activation. TNFR2 in its promoter contains binding sites for both
    STAT3 and c-AMP, the binding of which induces TNFR2 overexpression. Epigenetically,
    TNFR2 enhances IL-6 overexpression and down-regulates TET1 expression. As a result
    of TNFR2 activation, multiple proteins will be stimulated (CCL-2, PDL-1, IL-1β,
    IL-6, IL-8, IL-10, IL-23, M-CSF, MMP-9, COX-2/PGE2, TGF-β, CXCR4/CXCL-12, TNF-α,
    TNC, IFN-γ, and HIF-1α), leading to drug resistance, altered metabolism, migration,
    invasion, and the development of EMT. TNFR2, tumor necrosis receptor type 2; Mb-TNF-α,
    membrane-bound tumor necrosis factor; TRAF, TNF receptor associated factor; T2bs-C,
    TRAF2-binding site C; T2bs-N, TRAF2-binding site N; cIAP, cellular inhibitor of
    apoptosis; SHARPIN, shank-associated RH domain-interacting protein; HOIL-1-K63-Ub,
    heme-oxidized IRP2 ubiquitin ligase 1; HOIP-M1-Ub, HOIL-1-interacting protein;
    LUBAC, linear ubiquitin chain assembly complex; NIK, activate NF-κB inducing kinase;
    MEKK, MAP kinase/ERK kinase; TAK1, transforming growth factor-activated kinase
    1; TAP, TAK1-binding protein complex; PI3K, phosphoinositide 3-kinases; Akt, protein
    kinase B/serine-threonine kinase; CYLD, cylindromatosis; PFK-2, phosphofructokinase-2;
    PFKFB2, 3, 6-phosophofrcto-2-kinase/fructose-2, 6-biphosphatase 3; mTOR, mammalian
    (or mechanistic) target of rapamycin; EGFR, epidermal growth factor receptor;
    PTEN, phosphatase and tensin homolog; VEGF, vascular endothelial growth factor;
    ETK, endothelial/epithelial tyrosine kinase; BMX, marrow x-linked kinase; VEGFR2,
    vascular endothelial growth factor receptor 2; EMT, epithelial-mesenchymal transition;
    MMP-9, matrix metalloproteinase-9; FOXO3a, forkhead box O3a; JNK, c-jun N-terminal
    kinase; ERK, extracellular signal-regulated kinase; MUC-1 and MUC1-C, Mucin; c-MYC,
    cellular myelocytomatosis; STAT, signal transducer and activator of transcriptions;
    AP-1, activator protein-1; IL-6, interleukin 6; IL-8, interleukin 8; IL-10, interleukin
    10; IL-23, interleukin 23, M-CSF, macrophage colony stimulating factor; TET, ten-eleven
    translocation; COX-2, cyclooxygenase-2; PGE2, prostaglandin E2; TGF-β, transforming-growth
    factor β; IFN-γ, interferon gamma; HIF-1α, hypoxia inducible factor 1 alpha; NRP-1,
    Neuropilin-1; TNC, Tenascin C; ITBG3, integrin 3; FAK, focal adhesion kinase pathway;
    IKKs, IκB kinases; IGF1, insulin-like growth factor 1; HER2, human epidermal growth
    factor receptor 2
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TNFRSF1B
  - TRAF2
  - TANK
  - CYLD
  - BIRC3
  - PTEN
  - BMX
  - MAPK8
  - MAPK9
  - MAPK10
  - FOXO3
  - PFKFB3
  - PFKFB2
  - AGFG1
  - RIPK1
  - DCAF1
  - RPAIN
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - SHARPIN
  - PTK2
  - TRAF6
  - JUN
  - MAPK3
  - MAPK1
  - MAP3K7
  - NR2C2
  - TAP1
  - SEC14L2
  - TAP2
  - SEC14L3
  - KDR
  - MAP3K14
  - MAP4K4
  - NRP1
  - NELL1
  - MUC1
  - IKBKG
  - IKBKB
  - EPHA3
  - CHUK
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - IKBKE
  - CTNNB1
  - EGFR
  - SRC
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - ERBB2
  - MTOR
  - CUX1
  - NFKB2
  - OAS3
  - PMEL
  - SART3
  - TPX2
  - SND1
  - ASCC2
  - IL6
  - COX2
  - PTGS2
  - MTCO2P12
  - CXCR4
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - CXCL12
  - STAT3
  - IGF1
  - CD274
  - HIF1A
  - TNC
  - TNNC1
  - NFKB1
  - MMP9
  - CCL20
  - TGFB1
  - TGFB2
  - TGFB3
  - CXCL8
  - CSF1
  - IL1A
  - IL1B
  - IL10
  - TNF
  - IL37
  - IL23A
  - TET1
  - FOSL1
  - APRT
  - MFAP1
  - EBP
  - GLB1
  - SH3D19
  - RELB
  - Celecoxib
  - MG-132
  - Nucleus
  - PGE2
---
